Sequent Scientific board approves Q2 results, awaits NCLT ruling on merger

Sequent Scientific Limited announced its board of directors met on Friday, November 14, 2025, to approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. Consolidated results show total income of INR 8,714.30 million for the half-year, with profit after tax reaching INR 371.70 million. Standalone results indicate total income of INR 983.30 million for the half-year, with profit after tax at INR 64.50 million.

The board also addressed the composite scheme of amalgamation. The National Company Law Tribunal (NCLT) Hyderabad heard the matter on October 31, 2025, and reserved its order for pronouncement, with no effect of merger yet given in the financial results. Transaction costs related to this scheme amounted to INR 29.50 million for the six months ended September 30, 2025.

Additionally, the group reported a claim from a customer of INR 73.60 million, netted from revenue, for which the insurance company has been informed. In the prior year, gains from land/building sales by a German subsidiary and transfer of leasehold rights at Tarapur were recognized as 'Other Income'.